Patents Examined by Kamal Saeed
  • Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
    Patent number: 11370783
    Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: June 28, 2022
    Assignee: Angion Biomedica Corp.
    Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
  • Modulator of indoleamine 2,3-dioxygenase, preparation method and use thereof
    Patent number: 11369589
    Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: June 28, 2022
    Assignees: NANJING CAREPHAR SHENGHUI PHARMACEUTICAL CO., LTD., JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Yinlin Qin, Mei Su, Min Ji, Haidong Liu, Xi Zong, Xianzhi Wu
  • Compounds and methods for regulating, limiting, or inhibiting expression
    Patent number: 11369608
    Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dys-regulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: June 28, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Hui Li, Zhongqiu Xie
  • Sulcardine administration for treatment of acute atrial fibrillation
    Patent number: 11364223
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 21, 2022
    Assignee: HUYABIO International, LLC
    Inventors: Suzanne J. Romano, Gary T. Elliott
  • Composition including ADAM9 inhibitor and the use thereof
    Patent number: 11357759
    Abstract: The present disclosure relates to an ADAM9 inhibitor compound of formula (I), including salts, hydrates and stereoisomers thereof, compositions thereof, and methods of use therefor, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 14, 2022
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Yuh-Pyng Sher, Yang-Chang Wu, Juan-Cheng Yang, Ting-Ting Kuo, Chia-Chien Lo
  • Insecticidal compounds based on isoxazoline derivatives
    Patent number: 11357231
    Abstract: Compounds of formula III wherein R1, R2, L, Y1, Y2, Y3, and Y4 are defined in claim 1.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 14, 2022
    Assignee: SYNGENTA CROP PROTECTION LLC
    Inventors: Jérôme Yves Cassayre, Peter Renold, Myriem El Qacemi, Thomas Pitterna, Julie Clementine Toueg
  • Compounds for controlling arthropods
    Patent number: 11357755
    Abstract: The present invention relates to novel halogen-substituted compounds, to processes for their preparation and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: June 14, 2022
    Assignee: Bayer Animal Health GmbH
    Inventors: Joachim Telser, Ursula Krenz, Kirsten Boerngen, Andreas Turberg, Klein Sofia, Franziska Schmidt
  • 5-benzylidene-4-oxazolidinones
    Patent number: 11352333
    Abstract: Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: June 7, 2022
    Assignee: North Carolina State University
    Inventors: Joshua G. Pierce, Grant A. Edwards
  • Topically administrable formulation for the control and prevention of animal parasites
    Patent number: 11344532
    Abstract: The invention relates to novel liquid formulations suitable for topical administration to animals, which formulations comprise a fluorine-containing antiparasitic active compound and also triethyl phosphate, and to their use for the control and prevention of animal parasites.
    Type: Grant
    Filed: September 3, 2018
    Date of Patent: May 31, 2022
    Assignee: Bayer Animal Health GmbH
    Inventors: Wolfgang Wiehl, Petra Ohage-Spitzlei, Franziska Schmidt
  • Pharmaceutical composition
    Patent number: 11344535
    Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent storage stability. The pharmaceutical composition is provided to contain pemafibrate, a salt thereof or a solvate thereof, wherein a pH value of a solution produced by dissolving or dispersing the pharmaceutical composition in water is 7 or more.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 31, 2022
    Assignee: KOWA COMPANY, LTD.
    Inventors: Yuki Kuroiwa, Akito Minamizono
  • Therapeutic or prophylactic drug for dementia
    Patent number: 11344539
    Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: May 31, 2022
    Assignees: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, Tejin Pharma Limited
    Inventors: Takeshi Nishino, Shinsuke Kato, Masako Kato, Hidenori Suzuki, Ken Okamoto
  • Autotaxin inhibitor compounds
    Patent number: 11344533
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: May 31, 2022
    Assignee: Sabre Therapeutics LLC
    Inventors: John Howard Hutchinson, David Lonergan
  • Process for the preparation of a sulfonamide structured kinase inhibitor
    Patent number: 11332460
    Abstract: The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 17, 2022
    Assignee: ORION CORPORATION
    Inventors: Oskari Karjalainen, Pekka Pietikäinen
  • Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
    Patent number: 11318117
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 3, 2022
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Radiation mitigator and method of use thereof
    Patent number: 11311526
    Abstract: Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: April 26, 2022
    Assignees: Georgetown University, The Board of Regents of the University of Oklahoma
    Inventors: Milton L. Brown, Yali Kong, Courtney Houchen, Sripathi M. Sureban, Parthasarathy Chandrakesan
  • Pyrazole compound
    Patent number: 11312688
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: April 26, 2022
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors
    Patent number: 11304929
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: April 19, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Georg Dahmann, Matthias Treu, Bernd Wellenzohn, Stephan Karl Zahn
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 11299479
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 12, 2022
    Assignees: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Pharmaceutical composition
    Patent number: 11298340
    Abstract: Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and has excellent stability. A pharmaceutical composition is provided containing pemafibrate, a salt thereof or a solvate thereof and having a moisture content of 2.4 mass % or less.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 12, 2022
    Assignee: KOWA COMPANY, LTD.
    Inventors: Shin Sugimoto, Akito Minamizono
  • Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof
    Patent number: 11279717
    Abstract: The invention relates to functionalised dioxaborolane or dioxaborinane derivatives of formula (I), wherein R1 is covalently bonded to the boron atom by a carbon atom; one of R2, R3, R?3 or R4 is a radical of formula —X; or one of R1, R2, R3, R?3 or R4 is a radical of formula —X; and X is a functionalised radical. The invention relates to the method for preparing same and the uses thereof.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: March 22, 2022
    Assignees: ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Ludwik Leibler, Renaud Nicolay